SGLT2 Inhibitors Linked to Lower Autoimmune Disease Risk in Diabetes Patients

Modern research suggests a potential unexpected benefit of a common class of diabetes medications: a nearly 50% reduction in the risk of systemic autoimmune rheumatic diseases compared to another type of diabetes drug. The findings, published in Arthritis & Rheumatology, add to a growing body of evidence exploring the broader effects of SGLT2 inhibitors, originally designed to lower blood sugar.

SGLT2 Inhibitors and Autoimmune Disease Risk: What the Study Found

The population-based cohort study, conducted using health data from a Canadian province, followed over 229,000 adults with type 2 diabetes. Researchers compared those who started taking sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or dipeptidyl peptidase 4 (DPP4) inhibitors. The analysis focused on the incidence of several autoimmune rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s disease.

Whereas neither GLP-1 receptor agonists nor SGLT2 inhibitors showed a significant difference in overall autoimmune rheumatic disease risk compared to DPP4 inhibitors, a notable exception emerged. Patients taking SGLT2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic diseases. This means diseases affecting multiple organ systems, rather than localized conditions. The researchers followed patients for an average of 1.3 to 1.6 years.

Understanding the Medications

SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors are all oral medications used to manage type 2 diabetes. They work through different mechanisms to improve blood sugar control. GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), generally lead to the most significant weight loss. SGLT2 inhibitors offer modest weight loss and have demonstrated benefits for both cardiovascular and kidney health. DPP4 inhibitors are generally weight-neutral.

“SGLT2 inhibitors have clear benefit across the spectrum of heart failure, and are one of the four pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction. They are similarly kidney-protective, whether diabetes is present or not,” explains Dr. Derin Karacabeyli, a rheumatologist at Vancouver General Hospital and lead author of the study.

Why Might SGLT2 Inhibitors Offer This Protection?

The precise mechanism behind the observed reduction in systemic autoimmune rheumatic disease risk remains unclear. Researchers hypothesize that it could be related to the immunomodulatory effects of SGLT2 inhibitors. Preclinical studies in lupus-prone mice have shown that these drugs can reduce levels of autoantibodies and dampen inflammatory pathways.

However, Dr. Karacabeyli cautions against drawing firm conclusions. “We found that using SGLT2 inhibitors was associated with a nearly 50% reduction in the risk for systemic autoimmune rheumatic diseases, but the effect size was minor,” he said. “More research is needed to confirm this and explore why.” The researchers also acknowledge the possibility of confounding factors – that individuals prescribed SGLT2 inhibitors might have different underlying health characteristics that contribute to the observed effect.

Study Limitations and What It Doesn’t Tell Us

It’s important to note several limitations of the study. The average follow-up period of 1.5 years may not be long enough to detect a substantial reduction in risk for autoimmune diseases, which often develop over years or decades. The study population was also limited to adults with type 2 diabetes, so the findings may not be generalizable to other populations.

the study did not account for potential differences in healthcare access or other lifestyle factors that could influence autoimmune disease risk. The researchers also point out that the observed reduction in risk was relatively small in absolute terms – meaning that a large number of patients would demand to be treated with an SGLT2 inhibitor to prevent one case of systemic autoimmune rheumatic disease.

Putting the Findings into Context

The study does not suggest that people with diabetes should start taking SGLT2 inhibitors specifically to prevent autoimmune diseases. The primary indication for these drugs remains the management of type 2 diabetes. However, the findings offer intriguing evidence that these medications may have broader immunomodulatory effects beyond their glucose-lowering properties.

“we found that neither GLP-1 receptor agonists nor SGLT2 inhibitors altered the risk for developing autoimmune rheumatic diseases for adults with diabetes,” Dr. Karacabeyli explained. “This was reassuring, as we would have expected to witness a signal within the first year if these agents truly triggered the development of autoimmune rheumatic diseases.”

What’s Next for Research?

Further research is needed to confirm these findings and to elucidate the underlying mechanisms. Future studies could focus on specific subgroups of patients, such as those with obesity or pre-existing autoimmune risk factors. Longer-term follow-up studies are also needed to assess the long-term effects of SGLT2 inhibitors on autoimmune disease risk. Researchers are also exploring the potential for these drugs to be used as adjunctive therapies in the treatment of established autoimmune diseases.

The Canadian Institutes of Health Research provided support for this research. Readers should consult with a qualified healthcare professional for personalized medical advice and treatment recommendations.